Atara Biotherapeutics, Inc.: shareholders and insiders

ATRANASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$6.50

November 17, 2026Market cap $100M

What Ploutos Investor adds for Atara Biotherapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 4 fiscal years, from 2022
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 22% since Nov 10, 2026, when the 10-Q these figures come from was filed ($8.10 then, $6.29 on Nov 17, 2026). The figures date from before that move.10-Q
  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

Insiders and their shares

Purchases and sales by officers and directors from Nov 18, 2025 to Sep 4, 2026, from their own Form 4 filings.

7 Form 4s

Bought on the market

$5.7M

2 people

Sold on the market

$3.8M

4 people

From Nov 18, 2025 to Nov 18, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan0%
  • The rest100%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 18, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·bought $5.7M by 2 people·sold $3.8M by 4 people

  • 2025: no buys, no sales
  • 2026: bought $5.7M by 2 people, sold $3.8M by 4 people
  • Sep 4, 2026Brian N CherryDirector
    Kind
  • Aug 17, 2026AnhCo NguyenPresident and CEO
    Kind
  • Jul 22, 2026Redmile Group, LLCDirector
    Kind
  • Jul 22, 2026Redmile Group, LLCDirector
    Kind
  • Jun 11, 2026Brian N CherryDirector
    Kind
  • Jun 9, 2026William K HeidenDirector
    Kind
  • Jun 9, 2026Matthew K FustDirector
    Kind
  • Jun 9, 2026Gregory Austin CiongoliDirector
    Kind
  • May 18, 2026Yanina Grant-HuertaChief Accounting Officer
    Kind
  • May 18, 2026AnhCo NguyenPresident and CEO
    Kind
  • May 7, 2026EcoR1 Capital, LLC
    Kind
  • May 7, 2026Panacea Innovation Ltd
    Kind
  • Mar 2, 2026AnhCo NguyenPresident and CEO
    Kind
  • Mar 2, 2026AnhCo NguyenPresident and CEO
    Kind
  • Mar 2, 2026AnhCo NguyenPresident and CEO
    Kind
  • Mar 2, 2026AnhCo NguyenPresident and CEO
    Kind
  • Mar 2, 2026Yanina Grant-HuertaChief Accounting Officer
    Kind
  • Mar 2, 2026Yanina Grant-HuertaChief Accounting Officer
    Kind
  • Mar 2, 2026Yanina Grant-HuertaChief Accounting Officer
    Kind
  • Mar 2, 2026Yanina Grant-HuertaChief Accounting Officer
    Kind
  • Jan 12, 2026James Huang
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 11, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by ATRA's officers and directors from 2014 up to November 17, 2025, 12 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

6 Holders over 5%3 On a 13DAug 14, 2026 Latest filing
  • Adiumentum Capital Fund I LPwith 2 more persons
    Share of class20.0%
  • EcoR1 Capital, LLCwith 2 more persons
    Share of class17.4%
  • Panacea Innovation Limitedwith 5 more persons
    Share of class16.1%
  • Redmile Group, LLCwith 3 more persons
    Share of class9.90%
  • Adage Capital Management, L.P.with 2 more persons
    Share of class8.56%
  • Point72 Asset Management, L.P.with 2 more persons
    Share of class7.60%

What the holders on a 13D state as their purpose

From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.

  • Adiumentum Capital Fund I LP20.0%From the filing of May 16, 2025

    Item 4 of the Initial 13D is hereby amended and supplemented to add the following information: On May 14, 2025, Adiumentum agreed to purchase from the Issuer in connection with a registered offering (the "Registered Offering") an aggregate of (i) 75,572 shares (the "Shares") of the Issuer's common stock, par value $0.0001 per share (the "Common Stock"), and (ii) pre-funded warrants (each, a "Pre-Funded Warrant", and together, the "Pre-Funded Warrants") to purchase up to 227,000 shares of Common Stock, at a purchase price of $6.61 per share of Common Stock and $6.6099 per share of Common Stock issuable upon exercise of the Pre-Funded Warrants. The exercise price of each Pre-Funded Warrant…

    From the filing of May 16, 2025
  • Panacea Innovation Limited16.1%From the filing of May 21, 2025

    On May 16, 2025, James Huang was appointed to the Board of Directors (the "Board") of the Issuer in connection with the completion of an underwritten, registered offering of Common Stock and warrants to purchase common stock. General The Reporting Persons acquired the securities described in this Schedule 13D for investment purposes and intend to review their investments in the Issuer on a continuing basis. Any actions the Reporting Persons might undertake may be made at any time and from time to time without prior notice and will be dependent upon the Reporting Persons' review of numerous factors, including, but not limited to: an ongoing evaluation of the Issuer's business, financial…

    From the filing of May 21, 2025
  • Redmile Group, LLC9.9%From the filing of May 23, 2025

    The Reporting Persons acquired the securities covered by this Schedule 13D, including the New Warrants, for investment purposes, in the ordinary course of business. The Reporting Persons will routinely monitor a wide variety of investment considerations, including, without limitation, current and anticipated future trading prices for the Common Stock, the Issuer's operations, assets, prospects, business development, markets and capitalization, the Issuer's management and personnel, Issuer-related competitive and strategic matters, general economic, financial market and industry conditions, as well as other investment considerations. The Reporting Persons expect to discuss their investment…

    From the filing of May 23, 2025

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Jun 30, 2026 quarter end
  • Point72 (Cohen)
    In the quarter+254%
  • Citadel Advisors (Griffin)
    In the quarter
  • Millennium Mgmt (Englander)
    In the quarter-73%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 2.29% of its shares outstanding were held short, +8.8% since the report before.

Shares held short
350.3K
2.29%
Since the report before321.8K on Sep 30, 2026
+8.8%
8.7
40.3K
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 12.49M
  • Nov 15, 2023: Shares held short 8.16M
  • Nov 30, 2023: Shares held short 11.11M
  • Dec 15, 2023: Shares held short 10.13M
  • Dec 29, 2023: Shares held short 9.19M
  • Jan 12, 2024: Shares held short 7.33M
  • Jan 31, 2024: Shares held short 7.53M
  • Feb 15, 2024: Shares held short 10.87M
  • Feb 29, 2024: Shares held short 10.14M
  • Mar 15, 2024: Shares held short 11.03M
  • Mar 28, 2024: Shares held short 11.23M
  • Apr 15, 2024: Shares held short 11.45M
  • Apr 30, 2024: Shares held short 11.88M
  • May 15, 2024: Shares held short 11.62M
  • May 31, 2024: Shares held short 11.27M
  • Jun 14, 2024: Shares held short 10.78M
  • Jun 28, 2024: Shares held short 575.3K
  • Jul 15, 2024: Shares held short 540.0K
  • Jul 31, 2024: Shares held short 360.5K
  • Aug 15, 2024: Shares held short 378.5K
  • Aug 30, 2024: Shares held short 410.5K
  • Sep 13, 2024: Shares held short 463.0K
  • Sep 30, 2024: Shares held short 526.4K
  • Oct 15, 2024: Shares held short 639.2K
  • Oct 31, 2024: Shares held short 636.3K
  • Nov 15, 2024: Shares held short 519.5K
  • Nov 29, 2024: Shares held short 544.0K
  • Dec 13, 2024: Shares held short 551.5K
  • Dec 31, 2024: Shares held short 533.6K
  • Jan 15, 2025: Shares held short 547.8K
  • Jan 31, 2025: Shares held short 706.5K
  • Feb 14, 2025: Shares held short 674.6K
  • Feb 28, 2025: Shares held short 715.1K
  • Mar 14, 2025: Shares held short 723.3K
  • Mar 31, 2025: Shares held short 666.8K
  • Apr 15, 2025: Shares held short 662.2K
  • Apr 30, 2025: Shares held short 522.1K
  • May 15, 2025: Shares held short 412.9K
  • May 30, 2025: Shares held short 367.4K
  • Jun 13, 2025: Shares held short 285.8K
  • Jun 30, 2025: Shares held short 266.6K
  • Jul 15, 2025: Shares held short 268.0K
  • Jul 31, 2025: Shares held short 210.6K
  • Aug 15, 2025: Shares held short 196.2K
  • Aug 29, 2025: Shares held short 173.8K
  • Sep 15, 2025: Shares held short 161.5K
  • Sep 30, 2025: Shares held short 149.6K
  • Oct 15, 2025: Shares held short 128.8K
  • Oct 31, 2025: Shares held short 168.5K
  • Nov 14, 2025: Shares held short 176.8K
  • Nov 28, 2025: Shares held short 164.7K
  • Dec 15, 2025: Shares held short 166.9K
  • Dec 31, 2025: Shares held short 169.2K
  • Jan 15, 2026: Shares held short 1.02M
  • Jan 30, 2026: Shares held short 282.5K
  • Feb 13, 2026: Shares held short 209.3K
  • Feb 27, 2026: Shares held short 330.5K
  • Mar 13, 2026: Shares held short 313.3K
  • Mar 31, 2026: Shares held short 327.1K
  • Apr 15, 2026: Shares held short 318.0K
  • Apr 30, 2026: Shares held short 306.1K
  • May 15, 2026: Shares held short 546.5K
  • May 29, 2026: Shares held short 484.4K
  • Jun 15, 2026: Shares held short 492.4K
  • Jun 30, 2026: Shares held short 361.5K
  • Jul 15, 2026: Shares held short 577.6K
  • Jul 31, 2026: Shares held short 536.9K
  • Aug 14, 2026: Shares held short 477.3K
  • Aug 31, 2026: Shares held short 427.4K
  • Sep 15, 2026: Shares held short 404.3K
  • Sep 30, 2026: Shares held short 321.8K
  • Oct 15, 2026: Shares held short 350.3K

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading50.1% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 50.1% of the shares in the reported trades were short sales, against 43.9% in the 14 before.

Last 14 sessionsOct 29, 2026 – Nov 17, 2026
50.1%
The 14 beforeOct 9, 2026 – Oct 28, 2026
43.9%
Change
+6.2 pts
Short sales a dayon average, of 8,741 shares
4,380
More than atof 3,666 US-listed companies, same days
49%
Median of alleight in ten from 34.6% to 63.7%
50.3%
  • Oct 9, 2026: Short sales 34%
  • Oct 12, 2026: Short sales 16.8%
  • Oct 13, 2026: Short sales 90.9%
  • Oct 14, 2026: Short sales 21.8%
  • Oct 15, 2026: Short sales 52.7%
  • Oct 16, 2026: Short sales 44.8%
  • Oct 19, 2026: Short sales 49.5%
  • Oct 20, 2026: Short sales 30%
  • Oct 21, 2026: Short sales 37.7%
  • Oct 22, 2026: Short sales 37.1%
  • Oct 23, 2026: Short sales 24.2%
  • Oct 26, 2026: Short sales 51%
  • Oct 27, 2026: Short sales 82%
  • Oct 28, 2026: Short sales 61.4%
  • Oct 29, 2026: Short sales 36.1%
  • Oct 30, 2026: Short sales 37.1%
  • Nov 2, 2026: Short sales 41%
  • Nov 3, 2026: Short sales 71.4%
  • Nov 4, 2026: Short sales 55.9%
  • Nov 5, 2026: Short sales 42.5%
  • Nov 6, 2026: Short sales 19.5%
  • Nov 9, 2026: Short sales 23.5%
  • Nov 10, 2026: Short sales 73%
  • Nov 11, 2026: Short sales 51.7%
  • Nov 12, 2026: Short sales 37%
  • Nov 13, 2026: Short sales 46.2%
  • Nov 16, 2026: Short sales 36%
  • Nov 17, 2026: Short sales 77.7%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

6.33M Insiders' shares77.42% Of the company
  • EcoR1 Capital, LLCTenPercentOwner
    Directly–
  • James HuangDirector,TenPercentOwner
    Directly–
  • Gregory Austin CiongoliDirector
    Directly1.22M
  • Panacea Innovation LtdTenPercentOwner
    Directly–
  • Redmile Group, LLCDirector
    Directly636.9K
  • Brian N CherryDirector
    Directly166.5K
  • AnhCo NguyenPresident and CEO
    Directly132.8K
  • Pascal TouchonPresident and CEO
    Directly70.4K
  • Eric J HyllengrenEVP, CFO and COO
    Directly56.2K
  • Yanina Grant-HuertaChief Accounting Officer
    Directly49.6K
  • William K HeidenDirector
    Directly34.2K
  • Matthew K FustDirector
    Directly30.2K
  • Amar MuruganEVP, Chief Legal Officer
    Directly26.9K
  • Jill HenrichEVP, Chief Regulatory Officer
    Directly18.7K

A lower bound: it counts only the 14 officers and directors with a market trade since Nov 19, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

3 ETFs holding it0.01% The largest weight (IWC)
  • IWCiShares Micro-Cap ETF
    Weight in the fund0.01%
  • VXFVanguard Extended Market Index Fund
    Weight in the fund0.00%
  • VTIVanguard Total Stock Market Index Fund
    Weight in the fund0.00%

3 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

36 Managers, Q2 2026$51M Value of their positions
  • Q3 2025: Managers 37
  • Q4 2025: Managers 41
  • Q1 2026: Managers 33
  • Q2 2026: Managers 36

Institutional investors by quarter

The fund managers holding ATRA, quarter by quarter, from Q4 2014 to Q2 2025, 43 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 36 managers held 4.47M shares, worth $51M. During the quarter 4 opened a position, 1 closed one, 10 added and 8 trimmed.

The largest holders, Q2 2026

  • EcoR1 Capital
    In the quarter×15.6
  • Adage Capital Partners Gp
    In the quarter+21%
  • Point72 (Cohen)
    In the quarter+254%
  • Redmile Group
    In the quarter
  • Vanguard Capital Management
    In the quarter+13%
  • Mackenzie Financial
    In the quarter-26%
  • BlackRock
    In the quarter+6.9%
  • Geode Capital Management
    In the quarter+14%
  • Staley Capital Advisers
    In the quarter
  • Vanguard Fiduciary Trust
    In the quarter+28%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Atara Biotherapeutics's filings show?

Who buys and sells is one part of Atara Biotherapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about ATRA's shareholders

Didn't find what you were looking for?

Ask us
Have ATRA's insiders bought or sold?

From Jun 11, 2026 to Sep 4, 2026 Atara Biotherapeutics's insiders bought $1,000.0K and sold $40.9K of shares on the market. 0% of the sales were under set 10b5-1 plans.

Which well-known managers hold ATRA?

3 of the managers we track held the shares on Jun 30, 2026. The largest position was Point72 (Cohen)'s, worth $7.9M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.